IL6 and neoplasm: In conclusion, we found that raloxifene potently inhibits PDAC progression in vitro and in in vivo orthotopic tumor cell xenografts through a mechanism that involves binding and inhibition of gp130 and, thereby, abrogation of IL-6 signaling.